blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4034098

EP4034098 - ENHANCING CANCER THERAPY TREATMENT WITH BH3 MIMETICS [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  01.07.2022
Database last updated on 19.10.2024
FormerThe international publication has been made
Status updated on  03.04.2021
Most recent event   Tooltip28.09.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
The Regents of the University of Colorado, a body corporate
1800 Grant Street, 8th Floor
Denver, CO 80203 / US
[2022/31]
Inventor(s)01 / SHELLMAN, Yiqun
1638 S. Kingston Street
Aurora, Colorado 80012 / US
02 / TOBIN, Richard
1049 Florence Street
Aurora, Colorado 80010 / US
03 / MUKHERJEE, Nabanita
12614 East Kansas Drive Apt. L204
Aurora, Colorado 80012 / US
04 / NORRIS, David
5480 S. Holly Street
Englewood, Colorado 80111 / US
05 / MCCARTER, Martin D.
1673 Sand Lily Drive
Golden, 80401 / US
 [2022/31]
Representative(s)Dehns
10 Old Bailey
London EC4M 7NG / GB
[N/P]
Former [2022/31]Dehns
St. Bride's House
10 Salisbury Square
London EC4Y 8JD / GB
Application number, filing date20868227.825.09.2020
[2022/31]
WO2020US52790
Priority number, dateUS201962907179P27.09.2019         Original published format: US 201962907179 P
US202063056324P24.07.2020         Original published format: US 202063056324 P
[2022/31]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021062200
Date:01.04.2021
Language:EN
[2021/13]
Type: A1 Application with search report 
No.:EP4034098
Date:03.08.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 01.04.2021 takes the place of the publication of the European patent application.
[2022/31]
Search report(s)International search report - published on:US01.04.2021
(Supplementary) European search report - dispatched on:EP29.01.2024
ClassificationIPC:A61K31/519, A61K31/337, A61K31/704, A61K38/00, A61K31/635, A61P35/00, A61K39/395, A61K31/496, A61K45/06, A61K39/00, C07K16/28, G01N33/574
[2024/09]
CPC:
A61K45/06 (EP); A61K31/519 (EP,US); A61K31/496 (EP);
A61K31/635 (EP,US); A61K39/395 (EP); A61K39/3955 (US);
A61P35/00 (EP,US); C07K16/2818 (EP); G01N33/5743 (EP);
A61K2039/876 (EP); C07K2317/76 (EP); G01N2800/52 (EP) (-)
C-Set:
A61K31/519, A61K2300/00 (EP);
A61K31/635, A61K2300/00 (EP);
A61K39/395, A61K2300/00 (EP)
Former IPC [2022/31]A61K31/337, A61K31/704, A61K38/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/31]
TitleGerman:VERBESSERUNG EINER KREBSTHERAPIE MIT BH3-MIMETIKA[2022/31]
English:ENHANCING CANCER THERAPY TREATMENT WITH BH3 MIMETICS[2022/31]
French:AMÉLIORATION DU TRAITEMENT DE THÉRAPIE ANTICANCÉREUSE AVEC DES MIMÉTIQUES DE BH3[2022/31]
Entry into regional phase27.04.2022National basic fee paid 
27.04.2022Search fee paid 
27.04.2022Designation fee(s) paid 
27.04.2022Examination fee paid 
Examination procedure27.04.2022Examination requested  [2022/31]
17.11.2022Amendment by applicant (claims and/or description)
15.08.2024Date on which the examining division has become responsible
06.09.2024Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
Fees paidRenewal fee
27.01.2023Renewal fee patent year 03
27.12.2023Renewal fee patent year 04
27.09.2024Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
30.09.202203   M06   Fee paid on   27.01.2023
30.09.202304   M06   Fee paid on   27.12.2023
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]WO2018098534  (GARVAN INSTITUTE OF MEDICAL RES [AU]) [Y] 8,9 * page 2, paragraph 3 - page 3, paragraph 2 * * page 7, paragraph 3 * * page 55, paragraph 6 *;
 [XYI]WO2019161221  (ABBVIE INC [US]) [X] 1,2,4-7,11-15 * paragraph [0008] - paragraph [0010] * * paragraph [0024] - paragraph [0029] * * examples 1, 1A-1C, 5 * * figures 3, 12 * * claim - * [Y] 8,9,12-14 [I] 3,10;
 [Y]  - ANDRÁS KOTSCHY ET AL, "The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models", NATURE, (20161019), vol. 538, no. 7626, doi:10.1038/nature19830, pages 477 - 482, XP055571783 [Y] 8,9 * abstract * * page 480, column 1 - column 2, paragraph 1 * * figure 4 *

DOI:   http://dx.doi.org/10.1038/nature19830
 [Y]  - LEE ERINNA F. ET AL, "BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival", CELL DEATH & DISEASE, (20190424), vol. 10, no. 5, doi:10.1038/s41419-019-1568-3, XP093097343 [Y] 8,9 * abstract *

DOI:   http://dx.doi.org/10.1038/s41419-019-1568-3
 [Y]  - GARCÍA-ARANDA MARILINA ET AL, "Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, (20181208), vol. 19, no. 12, doi:10.3390/ijms19123950, page 3950, XP055806854 [Y] 12-14 * abstract * * pages 12-15, point 2.2 *

DOI:   http://dx.doi.org/10.3390/ijms19123950
International search[XY]US2016264678  (CHANG CHIEN-HSING [US], et al) [X] 1-2 * , entire document esp abstract, claims 1-5, para [0017] * [Y] 3;
 [Y]US2016287686  (DOW STEVEN W [US], et al) [Y] 3 * , entire document esp abstract *;
 [A]US2018357361  (FRENKEL FELIKS [RU], et al) [A] 1-3* , entire document *;
 [A]  - García-Aranda Marilina, Pérez-Ruiz Elisabet, Redondo Maximino, "Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy", International Journal of Molecular Sciences, (20181208), vol. 19, no. 12, page 3950, XP055806854 [A] 1-3 * , pg 1, 13, 14 *

DOI:   http://dx.doi.org/10.3390/ijms19123950
 [A]  - Li Zhaodong; He Shuning; Look A Thomas, "The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T- cell acute lymphoblastic leukemia cells'Leukemia1", Leukemia, (20190715), vol. 33, pages 262 - 266, XP036668811 [A] 1-3 * , entire document esp pg 262 col 2 para 1 *

DOI:   http://dx.doi.org/10.1038/s41375-018-0201-2
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.